Jul. 12 at 7:52 PM
$MRK 🚨 MUST buy
$SLS NOW
$MRK had billions lined up for
$RVMD , but RVMD passed. Now the clock is ticking on the Keytruda patent cliff. Keytruda brings in
$30 B a year. When that goes generic, Merck’s revenue falls off a cliff. They need a massive replacement NOW.
If
$SLS falls into the hands of
$LLY,
$JNJ, or
$PFE, Merck loses their oncology crown. Why? Because rivals would lock down the ultimate WT1 platform covering 20+ cancers.
Even worse, the buyer can just use a generic Keytruda with GPS to create an unstoppable super-combo, completely shutting Merck out of the market!
We ALREADY know the GPS + Keytruda combo is a powerhouse—just look at the survival rates in the advanced Ovarian cancer trials! Buy
$SLS for
$30B now, and it brings in
$300B over the next 10 years.
That’s the kind of math that makes a CEO look like an absolute brainiac. Big pharma threw
$6 BILLION at a FAILED AML drug. That puts the absolute floor at
$25/share right NOW. The math is undeniable. Pay up
$MRK
